[Does chronic therapy of hypertension with acebutolol or hydrochlorothiazide effect coronary risk factors?].
In 78 patients with mild or moderate hypertension, effect of acebutolol and hydrochlorothiazide on plasma lipids, lipoproteins, fibrinogen and plasma fibrinolysis time were investigated. 42 patients were treated with acebutolol for 18 months and 36 with hydrochlorothiazide for 24 months. It was shown that neither acebutolol nor hydrochlorothiazide induced significant alterations in investigated biochemical risk factors. The possible causes of controversy encountered in literature and analysis of factors which may influence the character and severity of metabolic disorders resulting from antihypertensive therapy were discussed.